Ames R
St Luke's-Roosevelt Hospital, New York, New York.
Drugs. 1988;36 Suppl 2:33-40. doi: 10.2165/00003495-198800362-00007.
Thiazide-type diuretic drugs modify the lipoprotein profile when used in the short term treatment of hypertension. Total cholesterol increases by 6 to 7% on average because of raised concentrations of low density or very low density lipoprotein cholesterol or both. High density lipoprotein cholesterol does not change. Spironolactone has a lesser effect on lipids than do thiazides. In contrast, the methylindoline compound, indapamide, a diuretic with vasodilator activity, has produced no adverse effects on lipids or lipoproteins. Long term data on thiazide monotherapy are sparse but suggest a persistence of the lipid effect for as long as 6 years of treatment. The clinical impact of these lipid changes is unclear. Although clinical trials have proved the benefit of lowering cholesterol on the incidence of coronary heart disease, the clinical significance of these diuretic-induced increases is unknown. A clinical trial will be required to resolve the issue by comparing antihypertensive drugs with and without adverse effects on the lipid profile. Because coronary heart disease is the most common complication of mild hypertension, and as diuretic-based regimens have not succeeded in curbing it, resolution of this concern is important.
噻嗪类利尿剂药物在短期治疗高血压时会改变脂蛋白谱。由于低密度脂蛋白胆固醇或极低密度脂蛋白胆固醇浓度升高,或两者均升高,总胆固醇平均升高6%至7%。高密度脂蛋白胆固醇不变。螺内酯对脂质的影响比噻嗪类药物小。相比之下,具有血管舒张活性的利尿剂甲基吲哚化合物吲达帕胺对脂质或脂蛋白没有产生不良影响。关于噻嗪类单药治疗的长期数据较少,但表明在长达6年的治疗中脂质效应持续存在。这些脂质变化的临床影响尚不清楚。虽然临床试验已证明降低胆固醇对冠心病发病率有益,但这些利尿剂引起的胆固醇升高的临床意义尚不清楚。需要进行一项临床试验,通过比较对脂质谱有或没有不良影响的抗高血压药物来解决这个问题。由于冠心病是轻度高血压最常见的并发症,而且基于利尿剂的治疗方案未能成功控制它,解决这一问题很重要。